{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:57:56Z","timestamp":1775044676866,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Several studies have demonstrated improvements in glucose control after initiation of automated insulin delivery (AID). This study aimed to evaluate glycemic outcomes and treatment-related barriers in subgroups of adults with type 1 diabetes (T1D) using AID systems in routine clinical practice. We analyzed data from 142 adults with T1D using Tandem Control IQ or MiniMed 780G. Correlation analyses were conducted to evaluate how changes in glycemic outcomes varied in relation to baseline characteristics. Mean age was 42 years, 40.8% were females, and median follow-up time was 1.7 years. Individuals with higher hemoglobin A1c (HbA1c) had less time below range (TBR) before starting AID (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). Effects on glucose control were similar irrespective of sex, prior insulin therapy, body mass index, and diabetes duration, but varied in relation to glucose control. Following AID initiation, the estimated reduction in HbA1c was 1.3% (14.3 mmol\/mol) in individuals with a baseline HbA1c of 8.6% (70 mmol\/mol), compared to 0.3% (2.9 mmol\/mol) in those with a baseline HbA1c of 6.7% (50 mmol\/mol) (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). Among individuals with a baseline TIR of 50% and 70%, the estimated increase in TIR following AID initiation was 19.0% and 7.2%, respectively (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). Greater reductions in HbA1c were associated with smaller reductions in TBR and vice versa (\n                    <jats:italic>r<\/jats:italic>\n                    \u2009=\u2009\u2212\u20090.29,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.003). Among MiniMed 780G users, older age correlated with greater improvements in TIR (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.005). Skin reactions tended to be more frequent in women (41%) than men (26%),\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.057. In conclusion,\u00a0AID system use was associated with substantial reductions in HbA1c in individuals with poor glycemic control. Clinically meaningful reductions in HbA1c were achieved also in individuals with an HbA1c closer to target who additionally gained greater reductions in TBR.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-37158-x","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T19:17:43Z","timestamp":1774984663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of automated insulin delivery systems on glucose control in subgroups of adults with type 1 diabetes in clinical practice over 2 years in Sweden"],"prefix":"10.1038","volume":"16","author":[{"given":"Ramanjit","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Imberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilan","family":"Seyed Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Hallstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Jendle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt-Olov","family":"Tengmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Folino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Lind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"37158_CR1","unstructured":"Swedish National Diabetes Register & Annual report, N. D. R. (2024). https:\/\/registercentrum.blob.core.windows.net\/ndr\/r\/NDR_-rsrapport-2024-nfsZyhug5.pdf. Accessed 4 June 2025."},{"issue":"18","key":"37158_CR2","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","volume":"381","author":"SA Brown","year":"2019","unstructured":"Brown, S. A. et al. iDCL trial research group. six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl. J. Med. 381 (18), 1707\u20131717. https:\/\/doi.org\/10.1056\/NEJMoa1907863 (2019). Epub 2019 Oct 16. PMID: 31618560; PMCID: PMC7076915.","journal-title":"N Engl. J. Med."},{"issue":"9","key":"37158_CR3","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa2004736","volume":"383","author":"MD Breton","year":"2020","unstructured":"Breton, M. D. et al. iDCL trial research Group. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl. J. Med. 383 (9), 836\u2013845. https:\/\/doi.org\/10.1056\/NEJMoa2004736 (2020). PMID: 32846062; PMCID: PMC7920146.","journal-title":"N Engl. J. Med."},{"issue":"2","key":"37158_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1089\/dia.2020.0388","volume":"23","author":"JE Pinsker","year":"2021","unstructured":"Pinsker, J. E. et al. Real-world patient-reported outcomes and glycemic results with initiation of Control-IQ technology. Diabetes Technol. Ther. 23 (2), 120\u2013127. https:\/\/doi.org\/10.1089\/dia.2020.0388 (2021). Epub 2020 Sep 10. PMID: 32846114; PMCID: PMC7868573.","journal-title":"Diabetes Technol. Ther."},{"key":"37158_CR5","doi-asserted-by":"publisher","unstructured":"Graham, R. et al. Real-world use of Control-IQ technology is associated with a lower rate of severe hypoglycemia and diabetic ketoacidosis than historical data: results of the Control-IQ observational (CLIO) prospective study. Diabetes Technol Ther. Oct 26. (2023). https:\/\/doi.org\/10.1089\/dia.2023.0341. Epub ahead of print. PMID: 37782904.","DOI":"10.1089\/dia.2023.0341"},{"issue":"12","key":"37158_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1089\/dia.2021.0165","volume":"23","author":"LH Messer","year":"2021","unstructured":"Messer, L. H. et al. Real-world use of a new hybrid closed loop improves glycemic control in youth with type 1 diabetes. Diabetes Technol. Ther. 23 (12), 837\u2013843. https:\/\/doi.org\/10.1089\/dia.2021.0165 (2021). Epub 2021 Jun 21. PMID: 34096789; PMCID: PMC8819505.","journal-title":"Diabetes Technol. Ther."},{"issue":"2","key":"37158_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1089\/dia.2021.0203","volume":"24","author":"JD Silva","year":"2022","unstructured":"Silva, J. D. et al. Real-world performance of the MiniMed\u2122 780G system: first report of outcomes from 4120 users. Diabetes Technol. Ther. 24 (2), 113\u2013119 (2022). PMID: 34524003; PMCID: PMC8817690.","journal-title":"Diabetes Technol. Ther."},{"issue":"9","key":"37158_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1089\/dia.2021.0097","volume":"23","author":"MD Breton","year":"2021","unstructured":"Breton, M. D. & Kovatchev, B. P. One year real-world use of the Control-IQ advanced hybrid closed-loop technology. Diabetes Technol. Ther. 23 (9), 601\u2013608. https:\/\/doi.org\/10.1089\/dia.2021.0097 (2021). Epub 2021 Apr 21. PMID: 33784196; PMCID: PMC8501470.","journal-title":"Diabetes Technol. Ther."},{"issue":"8","key":"37158_CR9","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1111\/dom.14424","volume":"23","author":"J Da Silva","year":"2021","unstructured":"Da Silva, J. et al. Real-world performance of the MiniMed\u2122 670G system in Europe. Diabetes Obes. Metab. 23 (8), 1942\u20131949. https:\/\/doi.org\/10.1111\/dom.14424 (2021). Epub 2021 May 27. PMID: 33961340.","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"37158_CR10","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1111\/dom.15023","volume":"25","author":"B Grassi","year":"2023","unstructured":"Grassi, B. et al. Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin america: substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system. Diabetes Obes. Metab. 25 (6), 1688\u20131697. https:\/\/doi.org\/10.1111\/dom.15023 (2023). Epub 2023 Mar 13. PMID: 36789699.","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"37158_CR11","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1111\/dom.14807","volume":"24","author":"J Casta\u00f1eda","year":"2022","unstructured":"Casta\u00f1eda, J. et al. Predictors of time in target glucose range in real-world users of the MiniMed 780G system. Diabetes Obes. Metab. 24 (11), 2212\u20132221. https:\/\/doi.org\/10.1111\/dom.14807 (2022). Epub 2022 Aug 1. PMID: 35791621.","journal-title":"Diabetes Obes. Metab."},{"key":"37158_CR12","doi-asserted-by":"publisher","unstructured":"Lombardo, F. et al. MiniMed 780G six-month use in children and adolescents with type 1 diabetes: clinical targets and predictors of optimal glucose control. Diabetes Technol Ther. ;25(6):404\u2013413. (2023). https:\/\/doi.org\/10.1089\/dia.2022.0491. Epub 2023 Mar 3. PMID: 36763343.","DOI":"10.1089\/dia.2022.0491"},{"key":"37158_CR13","unstructured":"Singh, R. et al. Effects, Safety, and treatment experience of advanced hybrid closed-loop systems in clinical practice among adults living with type 1 diabetes. J. Diabetes Sci. Technol. \u00a017:19322968241242386. doi: 10.1177\/19322968241242386. Epub ahead of print. PMID: 38629871; PMCID: PMC11571990. (2024)."},{"issue":"7","key":"37158_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/dia.2020.0646","volume":"23","author":"MJ Schoelwer","year":"2021","unstructured":"Schoelwer, M. J. et al. iDCL trial research group. Predictors of time-in-range (70\u2013180\u00a0mg\/dL) achieved using a closed-loop control system. Diabetes Technol. Ther. 23 (7), 475\u2013481. https:\/\/doi.org\/10.1089\/dia.2020.0646 (2021). Epub 2021 Mar 9. PMID: 33689454; PMCID: PMC8252894.","journal-title":"Diabetes Technol. Ther."},{"issue":"1","key":"37158_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/dia.2023.0261","volume":"26","author":"G Lepore","year":"2024","unstructured":"Lepore, G. et al. Advanced hybrid closed-loop system achieves and maintains recommended time in range levels for up to 2 years: predictors of best efficacy. Diabetes Technol. Ther. 26 (1), 49\u201358. https:\/\/doi.org\/10.1089\/dia.2023.0261 (2024). Epub 2023 Nov 8. PMID: 37902785.","journal-title":"Diabetes Technol. Ther."},{"issue":"14","key":"37158_CR16","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"Diabetes Control and Complications Trial Research Group et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl. J. Med. 329 (14), 977\u2013986 (1993).","journal-title":"N Engl. J. Med."},{"key":"37158_CR17","doi-asserted-by":"publisher","first-page":"l4894","DOI":"10.1136\/bmj.l4894","volume":"366","author":"M Lind","year":"2019","unstructured":"Lind, M. et al. HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ 366, l4894. https:\/\/doi.org\/10.1136\/bmj.l4894 (2019). PMID: 31462492; PMCID: PMC6712507.","journal-title":"BMJ"},{"issue":"25","key":"37158_CR18","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","volume":"353","author":"DM Nathan","year":"2005","unstructured":"Nathan, D. M. et al. Diabetes control and complications trial\/epidemiology of diabetes interventions and complications (DCCT\/EDIC) study research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl. J. Med. 353 (25), 2643\u20132653. https:\/\/doi.org\/10.1056\/NEJMoa052187 (2005). PMID: 16371630; PMCID: PMC2637991.","journal-title":"N Engl. J. Med."},{"issue":"12","key":"37158_CR19","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.2337\/dc23-0685","volume":"46","author":"E Joubert","year":"2023","unstructured":"Joubert, E. et al. Safety and efficacy of sustained automated insulin delivery compared with sensor and pump therapy in adults with type 1 diabetes at high risk for hypoglycemia: A randomized controlled trial. Diabetes Care. 46 (12), 2180\u20132187. https:\/\/doi.org\/10.2337\/dc23-0685 (2023). PMID: 37729080; PMCID: PMC10698222.","journal-title":"Diabetes Care"},{"key":"37158_CR20","doi-asserted-by":"publisher","first-page":"108752","DOI":"10.1016\/j.diabres.2021.108752","volume":"174","author":"H Chatwin","year":"2021","unstructured":"Chatwin, H. et al. The impact of hypoglycaemia on quality of life outcomes among adults with type 1 diabetes: A systematic review. Diabetes Res. Clin. Pract. 174, 108752 (2021). Epub 2021 Mar 17. PMID: 33722700.","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"6","key":"37158_CR21","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1177\/19322968241252613","volume":"18","author":"LB von Kobyletzki","year":"2024","unstructured":"von Kobyletzki, L. B. et al. Insulin pump therapy and adverse skin reactions with focus on allergic contact dermatitis in individuals living with diabetes mellitus: a systematic review and clinical-based update. J. Diabetes Sci. Technol. 18 (6), 1300\u20131312 (2024). Epub 2024 Jun 10. PMID: 38853748; PMCID: PMC11535278.","journal-title":"J. Diabetes Sci. Technol."},{"issue":"7","key":"37158_CR22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/dia.2018.0088","volume":"20","author":"AK Berg","year":"2018","unstructured":"Berg, A. K. et al. Skin problems associated with insulin pumps and sensors in adults with type 1 diabetes: a cross-sectional study. Diabetes Technol. Ther. 20 (7), 475\u2013482 (2018). Epub 2018 Jun 12. PMID: 29893593.","journal-title":"Diabetes Technol. Ther."},{"issue":"4","key":"37158_CR23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1932296820918894","volume":"15","author":"RS Rigo","year":"2021","unstructured":"Rigo, R. S. et al. Cutaneous reactions to continuous glucose monitoring and continuous subcutaneous insulin infusion devices in type 1 diabetes mellitus. J. Diabetes Sci. Technol. 15 (4), 786\u2013791 (2021). Epub 2020 May 9. PMID: 32389062; PMCID: PMC8258506.","journal-title":"J. Diabetes Sci. Technol."},{"issue":"4","key":"37158_CR24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/pedi.12652","volume":"19","author":"AK Berg","year":"2018","unstructured":"Berg, A. K. et al. High frequencies of dermatological complications in children using insulin pumps or sensors. Pediatr. Diabetes. 19 (4), 733\u2013740. https:\/\/doi.org\/10.1111\/pedi.12652 (2018). Epub 2018 Feb 26. PMID: 29484783.","journal-title":"Pediatr. Diabetes"},{"issue":"2","key":"37158_CR25","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1177\/1932296819870849","volume":"14","author":"NAM Asarani","year":"2020","unstructured":"Asarani, N. A. M., Reynolds, A. N., Boucher, S. E., de Bock, M. & Wheeler, B. J. Cutaneous complications with continuous or flash glucose monitoring use: systematic review of trials and observational studies. J. Diabetes Sci. Technol. 14 (2), 328\u2013337 (2020). Epub 2019 Aug 27. PMID: 31452386; PMCID: PMC7196864.","journal-title":"J. Diabetes Sci. Technol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37158-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37158-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37158-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:44:22Z","timestamp":1775040262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37158-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37158"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37158-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.J has been a lecturer\/member of the scientific advisory board in the following companies: Abbott, AstraZeneca, Eli Lilly, MiniMed, Nordic InfuCare, Novo Nordisk A\/S, Sanofi, Tandem and Ypsomed. M.L has been a consultant or received honoraria from Boehringer Ingelheim, Eli Lilly, Nordic InfuCare, Novo Nordisk and Rubin Medical. M.L has received research grants from Eli Lilly and Novo Nordisk, all outside of the submitted work. S.H has lectured for Novo Nordisk. All other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11001"}}